Close Menu

extraction technology

Emerging from stealth mode, the Toronto-based firm will use the platform to identify circulating tumor cells and spur drug development in the lung cancer space.

The group will validate Miraca's prototype extracellular vesicle isolation tool and antibody reagents using blood samples from breast and pancreatic patients.

Researchers have launched a startup called Fluxus to commercialize a platform based on the optofluidic chip for molecular analysis.

The firm also released pro forma results for its Q1 — reflecting the dispositions of the specialty product lines — showing $2.1 million less in revenues than previously reported, while its cash position increased 45 percent.

Qiagen licensed HandyLab's extraction technology for use in the sample prep process for its HPV assays.

LCS has entered a market varyingly referred to as sequence capture, target enrichment, and sequence enrichment. While the firms playing in this application area cannot agree on a name for it, they all agree that the market has the potential to become, in LCS' words, "very large."

Febit plans to debut the method at Cambridge Healthtech Institute's Next-Generation Sequencing conference in San Diego next month.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.